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Abstract
Background: Long-term local control in Glioblastoma is rarely achieved and nearly all patients relapse. In this study
we evaluated the clinical effect of different treatment approaches in recurrent patients.
Methods: Forty-three patients, with median age of 51 years were evaluated for salvage treatment: re-resection
and/or re-irradiation plus chemotherapy or chemotherapy alone. Response was recorded using the Response
Assessment in Neuro-Oncology criteria. Hematologic and non-hematologic toxicities were graded according to
Common Terminology Criteria for Adverse Events 4.0. Twenty-one patients underwent chemotherapy combined
with local treatment, surgery and/or radiation therapy, and 22 underwent chemotherapy only.
Results: The median follow up was 7 months (range 3–28 months). The 1 and 2-years Progression Free Survival
was 65 and 10 % for combined treatment and 22 and 0 % for chemotherapy alone (p < 0.01). The 1 and 2-years
overall survival was 69 and 29 % for combined and 26 and 0 % for chemotherapy alone (p < 0.01). No toxicity
greater than grade 2 was recorded.
Conclusion: These data showed that in glioblastoma recurrence the combination of several approaches in a
limited group of patients is more effective than a single treatment alone. This stress the importance of
multimodality treatment whenever clinically feasible.
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Background
Despite the use of maximal surgical resection, followed by
radiotherapy with concomitant and adjuvant temozolo-
mide (TMZ) improved survival in newly diagnosed glio-
blastoma (GBM), recurrence is still a significant problem
affecting more than 90 % of patients with this disease [1].
The median overall survival (OS) is 15–18 months and
less than 10 % of patients are still alive at 5 years [2].
Long-term local or regional control is rarely achieved and
nearly all patients relapse [3]. To date, several, non-
randomized, clinical trials on recurrence are available,
with heterogeneous patient cohorts, several treatment ap-
proaches, and different endpoints recorded. Different ap-
proaches are used including re-resection [4, 5],
chemotherapy [6, 7] or re-irradiation [8–11]. Surgery is
an effective option only in selected patients with youn-
ger age (70 years or less), a small tumor volume
(<50 cm3), a long interval time from previous surgical
resection and a preoperative KPS higher than 70 [4, 5].
Radiation therapy (RT) has been also proven to be use-
ful in recurrent glioblastoma. However, radiation oncol-
ogists have been highly reluctant to re-irradiate local
recurrences in the brain in relatively short interval. The
assumption that the central nervous system (CNS) tis-
sues are not able to repair radiation injury, limited the
use of this local approach, although some increasing
evidence exist of the use of radiotherapy in GBM
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retreatment [12]. These evidences, along with the im-
provement of neuro-imaging, and the availability of
modern high-precision radiotherapy techniques [8–11],
allowed a re-evaluation of RT in the clinical practice. In
addition, in the recent years, an increased number of clin-
ical trials tested in patients with glioblastoma recurrences,
the efficacy of single and/or combined chemotherapy
agents [13–21] as well as the benefit of anti-angiogenetic
drugs, such as bevacizumab, alone or associated with
chemotherapy [22–25] with encouraging results. In any
case, even in lack of a standard of care, chemotherapy re-
mains an important treatment option in recurrent GBM.
This is mainly due to the fact that a considerable number
of recurrences develop as diffuse infiltrating masses,
sometime involving also multiple distant sites. Indeed,
these patients are those in which the clinical performance
is usually deteriorating. Some recurrences, instead, de-
velop around the previous tumor site as defined masses.
In this particular setting of patients, the combined use of
various treatment approaches might be beneficial. Based
on these observations, the aim of the study was to evaluate
the survival benefits and toxicity profile of systemic
chemotherapy in recurrent brain glioma with or without
local therapy. Results were evaluated in terms of toxicity,
rate of progression free survival (PFS) and patients overall
survival (OS).
Methods
The present retrospective study includes patients with a
MRI evidence of recurrent or progressive GBM, occur-
ring at least 3 months after the end of RT, in order to
exclude pseudo-progression. At the initial diagnosis, all
patients had undergone open-surgery resection, followed
by radiotherapy with concomitant and adjuvant temozo-
lomide according to the Stupp scheme [1]. At the time
of recurrence, they were evaluated for salvage treatment.
From January 2006 to April 2014, 43 consecutive
patients were included in this retrospective study.
Twenty-two (51 %) were male and 21 (49 %) female with
a median age of 51 years (range 27–80 years). All pa-
tients were treated in agreement with the Helsinki dec-
laration. This study is a summary of a retrospective
analysis to the treatment charts. The Humanitas Insti-
tute’s ethical committee does not require a formal ap-
proval in case of retrospective study in which a formal
consent for handling patient medical data was obtained
at the time of admission according to the deliberation of
the national agency for clinical studies of 2008.
Patients characteristics and treatments at diagnosis are
shown in Table 1. Two groups of patients were analyzed.
Twenty-one (49 %) patients underwent combined treat-
ment, surgery and/or stereotactic radiation therapy plus
chemotherapy. Twenty-two (51 %) received chemotherapy
alone. The two groups were balanced in terms of patients
characteristics and disease status as detailed in Table 2. In-
clusion criteria for both groups are: outpatients with KPS
greater than 70, an interval time from previous surgery or
radiotherapy longer than 6 months and no multifocal
disease.
Surgery consisted in subtotal resection (SR) for all pa-
tients [26]. For radiation therapy, to precisely define the
exact extension of tumor, CT scans, enhanced T1-MRI,
FLAIR-MRI sequences and [11C]MET-PET were used.
Automatic rigid co-registration eventually manually cor-
rected was performed. The total dose prescribed was
25 Gy in 5 fractions. The hypofractionated approach was
chosen to improve logistic issues, patient compliance and
provide a more aggressive radiation treatment. Plans were
processed using intensity modulated therapy by means of
Table 1 Patients characteristics and treatments at diagnosis
No. (%)
Sex
Female 21 (49)
Male 22 (51)
Median age years (range) 51 (27–80)
MGMT promoter methylation status
Methylated 18 (42)
Unmethylated 8 (19)
Unknown 17 (39)
IDH mutation
Present 6 (14)
Absent 20 (47)
Unknown 17 (39)
KPS
100 11 (26)
90 19 (44)
80 2 (4)
70 11 (26)
Time to Relapse from initial diagnosis
≤ 12 months 21 (49)
> 12–24 months 13 (30)
> 24 months 9 (21)
Treatment at Initial Diagnosis
Surgery 43 (100)
Complete Resection (CR) 24 (56)
Subtotal Resection (SR) 5 (12)
Partial Resection (PR) 12 (28)
Biopsy 2 (4)
Radiotherapy 43 (100)
CT Concomitant and adjuvant (TMZ) 43 (100)
MGMT methylguanine-DNA methyltransferase, IDH isocitrate dehydrogenase,
KPS karnofsky performance status, TMZ Temozolomide
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volumetric modulated arc therapy in its RapidArc form
(Varian medical system, Palo Alto - USA) to ensure max-
imal dose conformity and rapid dose falloff toward critical
structures. Patients were treated with 6MV photon
beams generated by Varian linear accelerators. In both
groups second line chemotherapy was used and con-
sisted of Fotemustine (75–100 mg/m2), re-challenge
TMZ (50–100 mg/m2) and dose dense TMZ (100 mg/m2)
as 1 week off/1 week on scheme. TMZ was administered
to patients who demonstrated response to it during the
treatment at diagnoses.
Outcome evaluation
Clinical outcome was evaluated by clinical neurological
examination and brain MRI, 1 month after treatment
and then every 3 months at follow up. Response was
recorded using the Response Assessment in Neuro-
Oncology (RANO) criteria [27]. Hematologic and non-
hematologic toxicities were graded according to Common
Terminology Criteria for Adverse Events version 4.0.
Statistical analysis
Standard descriptive statistics (mean standard deviation
and cross tabulation analysis) was used to describe the
data general behavior. Survival and recurrence time ob-
servations were plotted according to the method of
Kaplan and Meier, and were starting from the date of re-
currence. Univariate analysis was performed with the
log-rank test to investigate the prognostic role of indi-
vidual variables. Backward stepwise multivariate Cox re-
gression model was used as a method to estimate the
independent association of a variable set with overall/
progression free survival. The model is performed in a
backward stepwise fashion with a probability to remove-
level set to 0.25. All analyses are sex and age adjusted.
Results
The median interval time from the initial diagnosis to the
recurrence was 13 months (range 6–78 months) and all
the 43 patients received further treatments. Hematologic
toxicity G1-2 was recorded in 8 patients (20 %). In no pa-
tients a delay of drug administration was required. No se-
vere acute hematologic toxicity requiring interruption of
the chemotherapy administration was recorded. Similarly,
no acute worsening of neurologic state occurred during
treatment, and neurological examination scores remained
stable. During follow up, an increase of antiepileptic drugs
(AEDs) and corticosteroids administration was needed in
the case of disease progression. At the same, asymptom-
atic radio-necrosis (G1-G2) was observed in 5 patients.
No G3-G4 radio-necrosis was recorded and none patients
needed re-surgery All patients were treated with 25Gy in
5 fractions with plan normalization at mean target dose so
that uniform prescription was obtained for all patients.
Dose to organs at risk was kept below tolerance levels for
all patients (these were near-to-maximum dose <12Gy for
brain stem, <8Gy for optic structures, <12Gy for cochlea).
The median follow up time from recurrence was 7 months
(range 3–28 months). At the time of last observation 12
patients (28 %) were alive and 31 (72 %) were dead. The 1-
year PFS was 41 %; the 1-year OS was 42 %. The median
PFS and OS from recurrence were 8 months (range 3–28
months; SD 7.4) and 11 months (range 3–38 months; SD
7.5) respectively. No prognostic factors (including age,
sex, performance status and recurrence volume as well as
IDH1 mutation and MGMT promoter status) resulted sig-
nificant to univariate analysis with exception of the differ-
ent modality treatment used; results are summarized in
Table 3. Considering the different treatment approaches,
patients submitted to combined treatment had the best
Table 2 Characteristics of patients in relation to different
therapeutic approaches: combined treatment (chemotherapy
CT, Surgery and Radiotherapy RT) versus chemotherapy only
according to gender, age, KPS , MGMT promoter status, IDH
mutation, time between initial diagnosis and recurrence and
recurrent tumor volume
Factors CT + surgery and/or
RT n. pts 21 (49 %)
CT only n.
pts 22 (51 %)
p value
Gender
Female 10 (49) 11 (50) 0.9
Male 11 (51) 11 (50)
Median age 50 years
(range 27–75 years)
53 years
(range 38–80 year)
0.4
MGMT promoter status
Methylated 9 9 0.9
Unmethylated 4 4
Unknown 8 9
IDH mutation
Present 5 1 0.17
Absent 8 12
Unknown 8 9
KPS
100 11 0 <0.01
90 5 14
80 2 0
70 3 8
Time to Relapse from initial diagnosis
≤ 12 months 6 15 <0.01
> 12–24 months 7 6
> 24 months 8 1
Median volume of recurrent disease (cm3)
< 35 cm3 10 10 0.7
≥ 35 cm3 11 12
MGMT methylguanine-DNA methyltransferase, IDH Isocitrate dehydrogenase
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outcome. The 1-year PFS was 65 % for combined treat-
ment; it resulted 22 % for chemotherapy alone (p < 0.01;
HR 2.5; CI95 % 1.21–5.28). The median PFS was 15
and 5 months respectively. The 1-year OS was 69 % for
the combined approach and 26 % for chemotherapy
alone (p < 0.01; HR 2.6; CI95 % 1.24–5.45). The median
OS was 17 and 6 months respectively. Figures 1 and 2
show the various survival actuarial curves.
Discussion
Available treatments for recurrent GBM include chemo-
therapy, RT, surgery, and of course, best supportive care.
In case of recurrence, the best treatment option is not
yet defined, and it is a matter of large debate.
To date, chemotherapy alone remains the treatment of
choice in recurrent GBM. Various anti-neoplastic agents
Table 3 Overall Survival (OS) and Progression free survival (PFS).
Univariate regression
p-value (OS) p-value (PFS)
Sex 0.24 0.23
Age 0.29 0.31
EOR at diagnosis 0.511 0.42
MGMT 0.14 0.11
Target Volume 0.87 0.96
IDH1 0.37 0.48
KPS 0.38 0.32
Treatment 0.01 0.004
KPS karnofsky performancs status, IDH isocitrate dehydrogenase, MGMT
methylguanine-DNA methyltransferase, EOR extension of resection
a
b
Fig. 1 Progression free survival (a) and Overall Survival (b)
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have been tested. Several dosing schedules of TMZ alone
or other agents combined was associated with a PFS at
6 months of 45 % and a 1 year OS of 20 % [14, 28–30].
In addition to TMZ based regimens, nitrosourea-based
regimens employing carmustine (BCNU) monotherapy
or lomustine (CCNU) combined with procarbazine and
vincristine (PCV) demonstrated similar results in terms
of survival at the cost of a greater hematologic toxicity
[31–33]. Some studies [22] evaluated the efficacy of dif-
ferent chemotherapy regimens, e.g. bevacizumab alone
or in combination with irinotecan, showing some syner-
gistic effect. In the present study, more than half of the
patients (55 %) received chemotherapy alone. The results
observed are comparable with those of literature with a
1-year PFS and 1-YEAR OS of 22 and 2 % respectively.
Details about some published studies are summarized in
Table 4. If chemotherapy alone is the main treatment
used, the results in term of disease control and survival
are still unsatisfactory; the addition of local treatments
could be a valuable approach to improve outcome for
recurrent HGG patients. The role of local treatment
needs still to be assessed. Surgery is not considered as a
standard of cure. In different published retrospective stud-
ies, the median OS in patients submitted to second sur-
gery was 6 months on the average [4, 5]. In a recent study
evaluating the effect, frequency, and complications of re-
peated surgical resection and value of additional adjuvant
therapy, it was highlighted that patients receiving CT or
Radiosurgery (SRS) had a significantly prolonged survival
compared to those undergoing surgery only. The median
a b
Fig. 2 Progression free survival (a) and Overall Survival (b) in relation with different treatment modalities. Solid line: combined treatment; dashed
line: radiotherapy alone (RT)
Table 4 Main published studies about patient with recurrent high grade glioma (III–IV) treated with chemotherapy alone
Authors Study N. PTS Treatment PFS (months) PFS 6 % OS (months)
Van Den Bent et al. [15] Phase II rand 108 BCNU or TMZ vs Erlotinib 2.4 24.1 7.3
54 1.8 11.4 7.7
Brandes et al. [33] Phase II 40 BCNU NA 17.5 7.5
Addeo et al. [18] Phase II 40 Fotemustine 6.7 61 11.1
Brada et al. [14] Phase II 126 TMZ 2.1 18 5.4
Wich et al. [29] Phase II 64 TMZ 1wk on/1 wk off 5.5 43.8 NA
Brada et al. [21] Phase II rand 87 TMZ 5 days 5 NA 8.5
81 TMZ 21 days 4.2 6.6
162 PCV 3.6 6.7
TMZ temozolomide, NA not available, mos months, PFS6 progression free at 6 months
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OS was 8.5 months compared to 3 months in patients
treated with surgery alone. The authors concluded that re-
surgery may be beneficial only if additional adjuvant treat-
ment options could be further employed [34].
More recently, the use of radiation therapy in case of
GBM recurrence has been revisited, evaluating the effect
of different modalities of dose delivery such as radiosur-
gery (SRS), fractionated stereotactic radiotherapy (FSRT)
or hypo-fractionated stereotactic radiotherapy (HSRT).
In this context, most authors recommend an interval of
at least 6 months between the first and the second irradi-
ation [35–37], in order to allow the repair of the radiation
damage [12, 38]. The effect of the use of re-irradiation
alone are interesting and comparable to those of other sin-
gle treatment modality, with a median survival of 9 months
and acceptable toxicity rates [39] To date, the largest trial
was performed by Fokas [36] on 53 GBM patients who
were re-irradiated using hypo-fractionated stereotactic
radiotherapy (HSRT). Re-irradiation was well tolerated (no
acute or late toxicity > grade 2), despite the relatively large
median tumor volumes (35.01 ml); the median survival
was 9 months, and the 1-year progression-free survival
(PFS) was 22 %. Recently, the role of concomitant chemo-
radiotherapy in recurrent setting has been also evaluated
[40–43] Combs analyzed the toxicity of TMZ combined
with FSRT on 6 patients undergone previous RT with
TMZ. They showed treatment feasibility maintaining low
toxicity without differences between TMZ-naïve and pre-
exposed patients. PFS at 6 months was 48 %, higher than
most reported data in the literature about HGGs re-
treatments [40]. Minniti [41] reported a series of patients
with recurrent GBM who received FSRT plus concomitant
TMZ. Median OS and PFS were 9.7 and 5 months, re-
spectively. Six- and 12-month OS rates were 84 and 33 %,
respectively, and the respective PFS rates were 42 and 8 %.
Arcicasa [42] reported a series of 24 patients, treated with
surgery, radiotherapy and chemotherapy using CCNU.
Median interval between RT courses was 14 months
(range 6–73). All patients received a complete course
of RT, and 22 of 24 patients received at least one course
of CCNU. Objective responses were seen in 14 evaluable
patients: 3 with partial response, 5 with stable disease, and
6 with progressive disease. Median time to progression
and overall survival from the onset of retreatment were
8.4 months (range 1–22) and 13.7 months (range 1–63+),
respectively. Glass [43] showed the feasibility of a com-
bined treatment consisting of fractionated stereotactic
radiotherapy (SRT) with cis-platinum (CDDP),with a me-
dian response duration of 4.6 months and median survival
of 13.7 months.
In the present study. 21 patients received chemotherapy
plus local treatments (surgery and/or radiation therapy).
The median time to progression was 15 months sand 1-
year PFS was 65 %; the median and 1-year OS was
17 months and 69 % respectively. These data improves
what reported in literature for HGG re-treatments. To
our knowledge, no studies comparing the effect of mul-
timodality treatments in GBM recurrence has been
published at now. As previously stated, the main aim of
this study was to evaluate the efficacy of combined treat-
ment compared with chemotherapy alone. Specifically, we
wished to verify if the combination of local treatments,
surgery and/or radiation therapy, to a systemic treatment
may improve the outcome of these patients. We observed
a median OS of 17 months versus 6 months and about
30 % of patients alive at 2 years versus 0 %. The addition
of surgery and/or RT is not burdened by an increase of se-
vere toxicity and no peri-operative mortality occurred.
This suggest, that the addition of local treatment may be
beneficial in a particular setting of patients. Only pa-
tients with recurrences limited to the site of the previ-
ous primary site and appearing as a well defined mass,
with a good performance status, and an interval time
between previous surgery and/or RT longer than
6 months were included in this analysis. Besides this,
the characteristics of the two groups were comparable.
The main limitations of the present study are the retro-
spective nature and the low number of patients. Our
data did not show and differences in relation to age,
KPS, IDH1 mutation and MGMT promoter status, in
our series did not modify survival. Probably, these re-
sults are related to the small sample size of the study.
Conclusion
This study suggest that in case of GBM recurrences,
the use of local treatment (surgery and/or radiotherapy)
achieves better results when compared with chemotherapy.
In this setting, the combined treatment achieves better PFS
and OS with minor toxicity. In addition, a multidisciplinary
evaluation is recommended to achieve the best choice of
treatment schedule for these highly selected patients.
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